Product Overview
【Drug Name】
Trade Name: Biliang
Generic Name: Metoprolol Tartrate Sustained-Release Tablets
English Name: Metoprolol Tartrate Sustained-Release Tablets
【Indications】
For the treatment of hypertension, angina pectoris, myocardial infarction, hypertrophic cardiomyopathy, aortic dissection, arrhythmias, hyperthyroidism, cardiac neurosis, etc.
【Main Ingredient】
1-Isopropylamino-3-[p-(2-methoxyethyl)phenoxy]-2-propanol L(+)-tartrate
【Specifications】
50mg x 20 tablets
【Interactions】
Combination with cimetidine or prior use of quinidine may increase metoprolol blood concentrations.
【Precautions】
1. Like other beta-blockers, metoprolol tartrate sustained-release tablets should generally be gradually withdrawn over 7-10 days. 2. For patients undergoing general anesthesia, discontinue use at least 48 hours before anesthesia. 3. Patients with insulin-dependent diabetes mellitus should use this medication under the guidance of a physician. 4. Use with caution during pregnancy and postpartum women.
【Dosage and Administration】
For hypertension: 0.1-0.2g daily, taken in the morning or evening, or as directed by a physician. For angina pectoris: 0.1-0.2g daily, taken in the morning or evening, or as directed by a physician.
【Storage】
Protected from light, store in a tightly sealed container. Shelf life: 24 months.
【Adverse Reactions】
A small number of patients may experience fatigue, gastrointestinal disturbances, and drowsiness in the initial phase of treatment, which resolve spontaneously with continued use. Nonspecific skin reactions and chills may occur occasionally.
【Interactions】
Combination with cimetidine or prior use of quinidine may increase metoprolol blood concentrations.
【Contraindications】
Significant bradycardia (heart rate <45/minute), cardiogenic shock, severe or acute heart failure, poor peripheral perfusion, second- or third-degree atrioventricular block, sick sinus syndrome, or severe peripheral vascular disease.
【Manufacturer】
Sichuan Ruikang Pharmaceutical Co., Ltd.
